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Abstract
Paget’s disease of bone (PDB) is a common disorder with a strong genetic component characterized by increased but
disorganized bone remodelling. Previous genome-wide association studies identiﬁed a locus on chromosome 14q32 tagged by
rs10498635 which was signiﬁcantly associated with susceptibility to PDB in several European populations. Here we conducted
ﬁne-mapping and targeted sequencing of the candidate locus to identify possible functional variants. Imputation in 741 PDB
patients and 2699 controls conﬁrmed that the association was conﬁned to a 60 kb region in the RIN3 gene and conditional
analysis adjusting for rs10498635 identiﬁed no new independent signals. Sequencing of the RIN3 gene identiﬁed a common
missense variant (p.R279C) that was strongly associated with the disease (OR = 0.64; P = 1.4 × 10−9), and was in strong linkage
disequilibrium with rs10498635. A further 13 rare missense variants were identiﬁed, seven of which were novel and detected
only in PDB cases. When combined, these rare variants were over-represented in cases compared with controls (OR = 3.72;
P = 8.9 × 10−10). Most rare variants were located in a region that encodes a proline-rich, intrinsically disordered domain of the
protein and many were predicted to be pathogenic. RIN3 was expressed in bone tissue and its expression level was ∼10-fold
higher in osteoclasts compared with osteoblasts. We conclude that susceptibility to PDB at the 14q32 locus is mediated by a
combination of common and rare coding variants in RIN3 and suggest that RIN3 may contribute to PDB susceptibility by
affecting osteoclast function.
Introduction
Paget’s disease of bone (PDB) is a common skeletal disorder that
affects up to 2% of individuals above the age of 55 in the UK and
other populations with founders of European descent (1,2).
Genetic factors play an important role in the pathogenesis of Pa-
get’s disease. Between 15–30% of patients have a positive family
history of the disease and in these families the disease shows an
autosomal dominantmode of inheritancewith incomplete pene-
trance (3–6). Mutations have so far been identiﬁed in the SQSTM1
gene as a cause of the disease (7,8) and these occur in up to 40% of
patients with familial PDB and up to 10% of those without a fam-
ily history of the condition. Genome-wide association studies
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(GWAS) have identiﬁed seven loci with robust evidence of associ-
ation with PDB (9,10). One of these loci, tagged by rs10498635
which is situated on chromosome 14q32.12, was strongly asso-
ciated with PDB in several European populations with a P-value
of 2.55 × 10−11 and an odds ratio of 1.44 (95% conﬁdence interval
1.29–1.60) for the associated single-nucleotide polymorphism
(SNP). The region of strongest association is ﬂanked by two re-
combination hotspots and contains only the RIN3 gene that en-
codes the Ras and Rab interactor protein 3 (11). RIN3 belongs to
a family of three proteins that playa role in endocytosis, vesicular
trafﬁcking and signal transduction by acting as guanine ex-
change factors (GEFs) for small GTPases. In particular, RIN3 has
been shown to act as a GEF for the Rab5 family of proteins includ-
ing Rab5 itself and Rab31 (12,13). The role of RIN3 in bonemetab-
olism has not speciﬁcally been studied, although it is known that
Rab proteins play a role in regulating osteoclast function through
effects on vesicular trafﬁcking (14). The aim of this study was to
conduct ﬁne-mapping of the RIN3 locus in order to identify pos-
sible functional variants that predispose to PDB.
Results
Imputation and association analysis
The chromosome 14q32 top-hit SNP rs10498635 identiﬁed by
GWAS (9) is located in intron 4 of the RIN3 gene and it is not pre-
dicted to have any functional effects. It is likely that this SNP is
marking for another functional variant in the region. In order to
reﬁne the association signals in this region,we carried out imput-
ation using the 1000 genomes data as reference in 741 PDB pa-
tients and 2699 controls that were included in our previous
genome-wide association study (9). This analysis conﬁrmed
that the area of strongest association was limited to a 60 kb re-
gion bounded by two recombination hotspots between exons 3
and 8 of RIN3. There was a consistent association signal of
about 1 × 10−5 for common imputed variants surrounding the
rs10498635 SNP (Fig. 1A). Some SNPs located outside this region
showed nominal association and to test for secondary signals
in this locus, we performed conditional analysis by adjusting
for rs10498635, but results showed that rs10498635 is the only
independent signal from this locus (Fig. 1B).
Resequencing of RIN3
We next investigated the possibility that previously unrecog-
nized variants within RIN3 might be responsible for the associ-
ation observed by conducting deep-sequencing of the 14q32
locus. This included a 210 kb region containing the entire RIN3
gene and about 20 kb of ﬂanking upstream and downstream
sequences using next-generation sequencing (see Materials
and Methods). This was carried out in 121 patients with PDB
and 49 unaffected controls from the UK. After quality control,
we detected 1272 genetic variants of which 1063 were single-
nucleotide variants (SNV) and the remaining were indels. We de-
tected 10 missense SNVs in the RIN3 gene of which four were
novel and not reported in public databases including dbSNP,
1000 Genome (www.1000genomes.org/) and NHLBI exome se-
quencing project (http://evs.gs.washington.edu/EVS/) (Supple-
mentary Material, Table S1). Of the 10 detected missense
variants, seven were rare variants (MAF < 1% in 1000 Genomes)
that were present only in cases but not in our controls, of
which four were not detected in public databases. Additionally,
three common missense variants were detected of which one
variant (p.R279C) showed a signiﬁcant association with PDB in
this group of cases and controls (P = 7.6 × 10−4). Non-coding
variants were annotated using Ensembl and ENCODE databases
to predict their functional signiﬁcance but only two variants
were located within predicted regulatory motifs (Supplementary
Material, Table S1); a rare variant detected in the promoter
region is predicted to disrupt a transcription factor MafG motif
(V-maf; musculoaponeurotic ﬁbrosarcoma oncogene homologue
G). This is amember of the smallMaf familyof proteins that act as
Figure 1. Regional association plots of the chr14q32 region showing the chromosomal position (based on NCBI human genome build 37) of SNPs plotted against −log10
P-values obtained from genotyped and imputed SNPs from 741 PDB cases and 2699 controls. SNPs are colour coded according to the extent of LD with rs10498635
(represented as a purple dot) which showed genome-wide signiﬁcance association in previous GWAS (9). Data before (A) and after (B) correction for rs10498635. The
estimated recombination rates (cM/Mb) from HapMap CEU release 22 are shown as light blue lines, and the blue arrows represent known genes in each region.
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transcriptional activators or repressors depending on their inter-
acting partner. Another rare variant was identiﬁed in the 5′UTR
region, located within a binding site of TAF1 transcription factor
as reported by the ENCODE database in three different cell lines
(lymphoblastoid, human embryonic stem cells and neuroblast-
oma). TAF1 (also known as TATA box binding protein associated
factor) is the largest component of the RNA polymerase IID
(TFIID) transcription factor complex.
We then extended the DNA sequencing by screening an add-
itional 125 PDB cases focusing on the promoter/5′UTR and coding
region of the RIN3 gene using the Sanger DNA sequencing
approach (see Materials and Methods). A summary of missense
and possible regulatory variants identiﬁed from this procedure
are shown in Supplementary Material, Table S2. We detected a
further six missense rare variants of which three were novel.
We next combined variants identiﬁed from next-generation
sequencing and Sanger sequencing and tested their association
with the disease using data from 1000 genomes and NHLBI as
controls. A summary of all missense and possible regulatory var-
iants are shown in Table 1. There was a highly signiﬁcant associ-
ation between the p.R279C variant (rs117068593) and PDB in
the sequenced samples compared with 1000 Genome controls
(OR = 0.60; 95% CI = 0.43–0.84; P = 3.1 × 10−3) and when compared
with NHLBI controls (OR = 0.50; 95% CI = 0.38–0.67; P = 2.0 × 10−6).
The p.R279C variant was also associated with PDB in our GWAS
cohort of 741 cases and 2699 controls (OR = 0.68; 95% CI = 0.58–
0.81; imputed P = 5.7 × 10−6). When data were combined from all
cases and controls, this variant showed strong evidence of asso-
ciation with the disease at a genome-wide level (OR = 0.64; 95%
CI = 0.55–0.74; P = 1.4 × 10−9). The p.R279C variant was found to
be in strong linkage disequilibrium (LD) with the top GWAS hit
rs10498635 (r2 = 0.96, D′ = 0.98; Fig. 2). Haplotype analysis in the
GWAS cohort identiﬁed only two haplotypes (rs10498635C–
rs117068593C; frequency in controls = 81.2%, rs10498635T–
rs117068593T; frequency = 18.2%, other haplotypes frequency
<0.2%). The risk haplotype rs10498635C–rs117068593C was over-
represented in the GWAS cases (86.4%) compared with controls
(81.2%; OR = 1.48; 95% CI = 1.25–1.74; P = 2.8 × 10−6). The C allele
of R279C was more common in familial cases (n = 9; 17.3%) com-
pared with that observed in sporadic cases (n = 45; 10.3%) but this
was not statistically signiﬁcant (P = 0.12). The other two common
coding SNPs (p.H215R and p.T425M) were detected but these did
not show a consistent association with the disease in the se-
quenced samples (Table 1) or in the GWAS cohort of 741 cases
and 2699 controls (P > 0.09). Additionally, these two SNPs showed
no evidence of association with the disease at a genome-wide
level in the combined data set (P > 1 × 10−4) and no LD was
found between these two SNPs and the top GWAS hit
rs10498635 (r2 < 0.15; Fig. 2).
Several rare variants (MAF < 1%) were also identiﬁed (Table 1)
of which twowere detected in familial cases, 12 in sporadic cases
and one was detected in both groups. Most rare variants were lo-
catedwithin exon 6 (10/15) in close proximity to the p.R279C com-
mon variant. Genotyping additional familymembers for variants
detected in familial cases revealed that the G613Awas transmit-
ted from an affected father (G/A) to an affected daughter (G/A).
It was not possible to check for familial transmission for the
A306T or rs368389701 as DNA was only available from the pro-
band. Many of the rare variants were more common in PDB
cases compared with controls. Individually, these did not reach
statistical signiﬁcance, but when information was combined for
all rare variants with an allele frequency of <1%, the results
were highly signiﬁcant (OR = 3.72; 95% CI = 2.38–5.82; P = 8.9 ×
10−10). Haplotype analysis showed that almost all rare variant’s
alleles (n = 24; 96%) occurred on the rs10498635C–rs117068593C
risk haplotype background.
Expression of RIN3 in bone cells
Analysis of RIN3mRNA expression in mouse tissue showed that
RIN3 expression was highest in lung followed by bone tissuewith
the lowest expression level detected in brain, muscle and pri-
mary mouse osteoblast (Fig. 3A). RIN3 mRNA expression in
mouse osteoclast cultured from bone-marrow cells was about
10-fold higher than that observed in primary mouse osteoblasts
(P < 0.001). RIN3 protein was also detected in human osteoclasts
by immunohistochemistry of bone sections from a patient with
giant cell tumour of bone (Fig. 3B).
In silico analysis of variant pathogenicity
Information on conservation and likely functional signiﬁcance
for the identiﬁedmissense variants as assessed by a suite of bio-
informatics tools (see Materials and Methods) are shown in
Table 1. The common variant p.R279C and four rare variants
(p.A141V, p.R231C, p.P386S and p.Y793H) showed high function-
ality score (≥4) based on six different bioinformatics tools. The lo-
cation of all missense variants in relation to RIN3 domains are
shown schematically in Figure 4. The RIN family of proteins
(RIN1, RIN2 and RIN3) share several common functional domains
including an Src-homology 2 (SH2) domain, a proline-rich region,
a vacuolar sorting protein 9 (VPS9) domain and an Ubiquitin-like
Ras association domain (11,16). The conserved VPS9 domain is
also present in the catalytic domains of guanine exchange factors
Vps9p and Rabex-5 (16). The common protein coding variants
and most of the rare variants that were associated with PDB (a
total of 10 out of 16), cluster in the proline-rich region of RIN3
that encompass amino acids 248–514 (Fig. 4).
Application of meta-server consensus disorder predictor pro-
grams metaPrDOS (17) and MetaDisorder (18) (data not shown)
along with PONDR VL-XT (15) suggest with high conﬁdence that
the proline-rich region corresponds to a region of extended in-
trinsic disorder (Fig. 4) in keeping with data that suggests that
out of the 20 common amino acids, proline is the most dis-
order-promoting (19). Because currently available pathogenicity
predictors are mainly structure- and/or conservation-based,
their applicability in examining variants located in unstructured
regions or regions of low sequence conservation in proteins (such
as those variants located within the proline-rich disordered
region of RIN3), are limited (20). The functional impact of these
variants was therefore further assessed by their potential to
alter disorder propensity, a known disease-mechanism, using
PONDR, as was previously undertaken (20,21) (Fig. 4). The com-
mon variant p.R279C resides within a PXXP motif, a functional
motif in several proteins that confers binding to a range of do-
mains, including SH2 and SH3 (22); analysis of p.R279C showed
a subtle tendency of disorder-to-order transition. We similarly
analysed the other nine variants that reside within the proline-
rich disordered region (Fig. 4). A noticeable increase in disordered
propensity was found for R427Q, however, only a subtle disor-
dered-to-ordered structural transition is predicted for P386S
and P477S and no change is discernible for the other variants.
The location and predicted impact of missense variants that
occur within structured domains was also assessed further by
manually created three-dimensional (3-D) homology models.
One missense variant (p.A141V) lies within the SH2 domain
and three others (p.G613A, p.D771N and p.Y793H) reside within
the VPS9 domain. While two of these mutations p.A141V (SH2)
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Table 1. Summary of all missense and possible regulatory variants identiﬁed in RIN3
Variant ID Position (hg19) Reference
allele
Sample
allele
Gene region Protein variant AF casesa (%) AF 1000Gb (%) P-valuec AF NHLBId N (%) P-valuee Functional
prediction scoref
N/Ag 92 979 351 A G Promoter — 2/492 (0.41) 0 (0.0) 0.15 — — NFE2L1/MafG
rs368389701h 92 980 256 C A 5′UTR — 1/492 (0.20) 0 (0.0) 0.39 — — TFBS (TAF1; POLR2A)
N/Ag 93 081 806 C T Exon 4 p.A141V 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 5
rs3829947g,h 93 118 038 A G Exon 6 p.H215R 257/492 (52.2) 427 (56.3) 0.15 4902 (57.0) 0.04 0
N/Ag 93 118 085 C T Exon 6 p.R231C 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 4
rs147329151g 93 118 145 C A Exon 6 p.Q251K 2/492 (0.41) 0 (0.0) 0.15 2 (0.02) 0.02 1
rs117068593g,h 93 118 229 C T Exon 6 p.R279C 54/492 (10.97) 129 (17.0) 3.1 × 10−3 1687 (19.6) 2.0 × 10−6 4
N/Ag 93 118 260 T C Exon 6 p.L289P 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 1
N/Ag 93 118 268 T C Exon 6 p.C292R 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 2
N/Ag 93 118 274 C T Exon 6 p.P294S 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 1
N/Ah 93 118 310 G A Exon 6 p.A306T 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 0
rs201271121g 93 118 550 C T Exon 6 p.P386S 1/492 (0.20) 0 (0.0) 0.39 0 (0.0) 0.05 4
rs3742717g,h 93 118 668 C T Exon 6 p.T425M 77/492 (15.65) 165 (21.8) 7.5 × 10−3 1458 (16.9) 0.45 1
rs74074811g 93 118 674 G A Exon 6 p.R427Q 2/492 (0.41) 0 (0.0) 0.15 10 (0.12) 0.11 0
rs74074812g 93 118 823 C T Exon 6 p.P477S 1/492 (0.20) 0 (0.0) 0.39 2 (0.02) 0.14 3
rs12434929g,h 93 119 232 G C Exon 6 p.G613A 4/492 (0.81) 7 (0.92) 0.24 57 (0.66) 0.19 1
rs145292991g 93 125 790 G A Exon 7 p.D771N 1/492 (0.20) 0 (0.0) 0.39 2 (0.02) 0.14 3
rs147042536g 93 142 861 T C Exon 8 p.Y793H 5/492 (1.02) 5 (0.66) 0.19 54 (0.63) 0.11 6
aAllele frequency (AF) shown as number of alleles observed/total number of alleles.
bAllele frequency in European subjects from 1000 Genomes (n = 379).
cP-value from testing sequenced cases (n = 246) and European subjects from 1000 Genome.
dAllele frequency in European-American subjects in NHLBI data set (n = 4300).
eP-value from testing sequenced cases (n = 246) and European-American subjects from NHLBI data set.
fFor missense variants, as assessed by SIFT, PolyPhen-2, Condel, MutationTaster, GERP conservation score and Grantham score (see Materials and Methods).
gVariant detected in sporadic cases.
hVariant detected in familial cases.
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and p.D771N (VPS9) are solvent-exposed and thus are unlikely
to impact on the stability of their domain structures, the possi-
bility that they impact on protein–protein interaction remains.
The p.G613A, however, present in the N-terminal helical bundle
of VPS9, is not conserved even inmouse RIN3, and is likely to be a
neutral substitution consistent with data from automated func-
tional prediction tools (Functionality score = 1; Table 1). The
p.Y793H variant that was suggested to be a ‘potentially dam-
aging’ substitution with high probability on the other hand
(Functionality score = 6; Table 1) is largely buried within the
structurally and functionally important αV4 helix (23) in the
VPS9 domain. Indeed, in silico mutagenesis of p.Y793H using
FoldX (24,25) to assess its impact on structural stability produces
a mean ΔΔG energy value ∼2 kcal/mol, suggesting that this
mutant is destabilizing (24,26,27) where severely reduced struc-
tural stability is inferred by a ΔΔG > 1.6 kcal/mol. Similar mean
ΔΔG energy values were obtained upon mutating the equivalent
Tyrosine residues in each of the three templates used for model-
ling RIN3-VPS9, corroborating this result (Supplementary Mater-
ial, Table S3).
Discussion
The present study provides strong evidence that common and
rare coding variants within the RIN3 gene predispose to PDB. As-
sociation studies using imputation with the 1000 genomes panel
as reference showed that rs10498635 is the only independent as-
sociation signal in this region and suggested that the association
was most probably driven by the coding variant p.R279C which
was in strong LD with rs10498635. Haplotype analysis identiﬁed
a common haplotype (rs10498635C–rs117068593C) associated
with increased risk of PDB. Two other common variants (p.H215R
and p.T425M) were detected in RIN3, but these showed no consist-
ent association with the disease and they were not in LD with the
GWAS top hit SNP rs10498635.
We also identiﬁed several rare protein coding variants which
were strongly over-represented in PDB cases compared with con-
trols (OR = 3.72; P = 8.9 × 10−10). Although the disease status was
unknown for the 1000 genomes and NHLBI control cohorts, con-
tamination of controls with undiagnosed cases is unlikely to
inﬂuence the results substantially given that Paget’s disease is
a relatively uncommon condition occurring in about 1% or less
of the European populations.
We found that RIN3 was expressed in bone tissue and its ex-
pression level was ∼ 10-fold higher in osteoclasts compared
with that observed in osteoblasts. RIN3 protein was also detected
in osteoclasts from the curetted specimens obtained surgically
from a patient with a giant cell tumour of bone. These data sug-
gest that RIN3 may contribute to PDB susceptibility by affecting
osteoclast function, consistent with the fact that PDB is consid-
ered a disease of abnormal osteoclast biology. However, further
functional studies will be required to investigate the role of
RIN3 in osteoclast differentiation.
Detailed in silico prediction identiﬁed two groups of variants;
those located within structured domains of the protein (SH2
and VPS9) and those in the proline-rich disordered region that
may be disease-causing. The common disease-associated vari-
ant p.R279C and most of the rare variants are located within
the proline-rich disordered region of RIN3. Typically, disordered
protein regions perform important cellular roles and bind to a
range of protein partners owing to inherent structural plasticity
(19). Interestingly, a recent study found that nearly 20–25% of dis-
easemutations mapped to predicted disordered regions and 20%
of disease mutations in these regions cause local disorder-to-
order transitions (21). The p.R279C had a high functionality
score as predicted by pathogenicity predictors (Table 1), whereas
detailed in silico prediction analysis showed only a subtle order-
Figure 2. Linkage disequilibrium (LD) plot of common missense coding variants
detected by DNA sequencing of RIN3 and the top GWAS SNP rs10498635.
Figure 3. Expression of RIN3 in various tissues. (A) RIN3mRNA expression in the
indicated mouse tissues and in cultured primary osteoclasts (OC) and primary
calvarial osteoblasts (OB). RIN3 mRNA expression was normalized to 18 s rRNA
and values are presented as mean ± SEM from three independent experiments.
*P < 0.05 from all, **P < 0.05 from all except brain and muscle, ***P < 0.05 from all
except OB and muscle, ****P < 0.05 from all except brain and OB. (B) Representative
pictures of FFPE sections of lung (left) and giant cell tumour of bone (right) stained
by immunohistochemistry for RIN3. Arrows pointing at stained osteoclasts.
Magniﬁcation ×40.
Human Molecular Genetics | 5
 at Edinburgh U
niversity on M
arch 18, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
enhancing effect (Fig. 4) consistent with the fact that this is a
common variant with a modest effect size (OR = 0.64). Three
other rare variants were predicted to have an impact on disorder
propensity of this region of the protein and are thus likely to be
solvent-exposed accessible to potential protein-interaction part-
ners. Further functional analyses will be required to investigate
the impact of variants located in the disordered region of RIN3.
The p.Y793H variant located in the VPS9 domain is predicted
to be pathogenic by bioinformatics tools as well as by our hom-
ologymodelling suggesting that this variant is highly likely to im-
pair RIN3 function. Furthermore, functional studies have shown
thatmutations affecting the VPS9 domain of RIN3 impairs its GEF
activity for Rab31 (12) consistentwith thebioinformatics prediction.
It is interesting to note that the less common rs117068593T
allele (encoding for cysteine at position 279) was associated
with reduced risk of PDB, whereas the rare variants, when com-
bined, were associated with increased risk of the disease. One ex-
planation for this discrepancy comes from haplotype analysis
which showed that almost all rare variant’s alleles occurred on
the risk rs117068593C haplotype background suggesting that
the risk rs117068593C allele could be acting as a marker for rare
variants. However, despite its weak predicted functional effect,
Figure 4. (A) The schematic of the RIN3 protein is presentedwith domains delineated andmissense variants from this studymapped. (B) The 3-D homologymodels of the
RIN3 SH2 and VPS9 domains are shownwith location of variants indicated on structure. (C) The PONDRVL-XT disorder predictions (15) for wild-type and RIN3 variants are
also presented drawn to scale with the schematic in the upper panel. The green bar denotes location of an extended region of predicted disorder that corresponds to the
proline-rich region. Disorder predictions were carried out on full length wild-type and mutated protein sequences, generated by changing each of the variant residues
individually in silico using PONDR. PONDR disorder scores <0.5 signiﬁes predicted order, while ≥0.5 signiﬁes predicted disorder. Only a subtle disordered-to-ordered
structural transition is predicted for R279C, P386S and P477S, while an increase in disordered propensity is noticeable for R427Q. No change is discernible for the other
variants. Only two out of the 16 variants (H215R and R231C) are located outside the modelled domains and disordered region, and hencewere not assessed on this basis.
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it is possible for the rs117068593T allele to have a functional im-
pact on the protein leading to protective effect on the disease.
The pathogenicity predictors do not discriminate betweenmuta-
tions that confer loss of function, gain of function, or protective
effects; theymerely suggest a two-state predictionwhere amuta-
tion is tagged as either ‘benign/neutral’ or ‘deleterious/pathogen-
ic’. Furthermore, it has been shown that differentmutationsmay
have opposing impact on the protein function depending on their
location and on the nature of the amino acid change involved. For
example, certain missense mutations in LRP5 gene cause high
bone mass (28) and other conditions with increasing bone dens-
ity (29), whereas other missense mutations in the same gene
cause osteoporosis pseudoglioma syndrome (30).
While our in silico studies also revealed that some of the rare
variants were predicted to be benign this does not exclude the
possibility that theymay be functionally important. A notable ex-
ample of this in PDB is the case of the disease-causing p.P392L
mutation in SQSTM1 which is predicted to be benign by bio-
informatics tools but impairs the ubiquitin binding function of
SQSTM1 (31).
More research will now be required to evaluate the role that
RIN3 plays in bone metabolism and in the pathogenesis of
PDB. The most extensively studied member of the RIN family is
RIN1 which is known to affect signalling and stability of the
EGF-receptor and other receptor tyrosine kinases (16,32–34). It
is conceivable that RIN3 could act in a similar way to regulate sig-
nalling in osteoclasts but further studies will need to be done to
investigate this hypothesis.
In conclusion, our study provides strong evidence that RIN3 is
the predisposing gene for PDB at the 14q32 locus and raises the
possibility that RIN3 may play a previously unsuspected role in
regulating bone metabolism.
Materials and Methods
Study population
Targeted sequencing of the entire RIN3 gene was performed on
leucocyte DNA from 121 patients with PDB and 49 controls. The
PDB group comprised 95 cases who had participated in the
PRISM study (35) and 26 familial cases in which one affected sub-
jectwas selected fromeach family. The control groupwas selected
from the PRISM control cohort (n = 40) and unaffectedmembers of
familial cases (n = 9). Sanger sequencingwasperformedona group
of subjects comprising 101 caseswith PDBwhohadparticipated in
the ZIPP study and 24 additional cases selected from the PRISM
study. Both groups of patients were selected on the basis that
they did not carry mutations in the SQSTM1 gene and had an
age at diagnosis of PDB of less than 65 years. All subjects used
for DNA sequencing were of European descent and for the major-
ity of cases (60%) genome-wide SNP datawas available and ethni-
city was conﬁrmed by multidimensional scaling analysis
(Supplementary Material, Fig. S1A). For the remaining subjects,
ethnicity was determined by detailed questionnaire.
Imputation
The imputation analysis was performed in 741 PDB patients and
2699 controls who had participated in previous genome-wide as-
sociation studies in PDB as previously described (9). All subjects
were of European descent as determined by multidimensional
scaling analysis of genome-wide SNP data (see Supplementary
Material, Fig. S1B). Genotype imputation across the 14q32 locus
was performed using MaCH (36), and the 1000 Genome European-
phased haplotype data (from phase I version 3) were used as a
reference. We excluded SNPs with minor allele frequency of
<0.01 and those with poor imputation quality based on the esti-
mated correlation between imputed and true genotypes (r2 < 0.3).
Imputed SNPs were tested for association using ProbABEL soft-
ware (37) implementing a logistic regression model in which
the allelic dosage of the imputed SNP was used to adjust for un-
certainty in imputed genotypes. Regional association plots were
generated using the LocusZoom tool (38).
Sequencing
Sequencing of RIN3 was performed using next-generation se-
quencing approach. A 210 kb region containing the entire RIN3
gene and an ∼20 kb ﬂanking region on either side was captured
using theHaloPlex target enrichment kit fromAgilent and follow-
ing the manufacturer guidelines (Agilent, USA). Libraries were pre-
pared and labelled with barcodes for sequencing on the Illumina
HiSeq2000platform.Sequence reads (Fastq)weremapped to the ref-
erence human genome (hg19/b37) using the Burrows-Wheeler
Aligner (BWA) package (39). Duplicate reads were removed using
Picard version 1.89 (http://picard.sourceforge.net) and Genome
Analysis Toolkit ver 1.6 (GATK; http://www.broadinstitute.org/
gsa/wiki/index.php/Home_Page) was used for local re-alignment
of the mapped reads around potential indel sites. Base quality
(Phred Scale) scores were recalibrated using GATK and calling of
SNPs and indel variants was performed using the GATK uniﬁed
genotyper. The mean target coverage was ×47, and 98.45% of
aligned bases hadquality scores >20.We excludedSNVswith qual-
ity score <20, those with coverage <×5 and indel variants.
The Sanger sequencing was performed on the promoter, cod-
ing exons and intron–exon boundaries of RIN3 according to
standard techniques using primer sequences described in Sup-
plementary Material, Table S4. All primers were tagged with
M13 sequences (GTAGCGCGACGGCCAGT on the 5′ extremity of
the forward primers and CAGGGCGCAGCGATGAC on the 3′ ex-
tremity of the reverse primers). For standard PCR reactions, we
used CM-102A Ready Mix Custom PCRMaster mix (Thermos scien-
tiﬁc) and primers at a ﬁnal concentration of 0.83 µ. The melting
temperature was 94°C for 1 min, annealing 58°C for 1 min and ex-
tension 72°C for 1 min for 30 cycles, preceded by an initial denatur-
ation step of 94°C for 4 min, and ﬁnal extension step of 72°C for
10 min. For reactions across CG-rich regions, a similar protocol
was used except that we used Qiagen multiplex PCR master mix
and Quaigen Q buffer. Here, the annealing temperature was 56°C,
the number of cycles were 35, and the initial denaturation step
was extended to 15 min. Following PCR, the reaction products
were cleaned using the Agencourt CleanSEQ kit (Beckman Coulter)
prior to sequencing and the sequencing reactions were performed
using big dye version 3.1 reagents with M13 tagged forward and re-
verse primers. The sequencing reactions were analysed using the
ABI 3130 and 3730 sequencers (Applied Biosystems). The sequen-
cing results were analysed by the Mutation surveyor® V3.30 soft-
ware (Softgenetics, State college, PA, USA) and compared with the
reference sequences using Alamut V2.1 software (Interactive Bio-
Software, Rouen, France). The primer sequences and reaction con-
ditions used are provided in Supplementary Material, Table S4. As
part of quality control measures, 15 samples were sequenced
using both platforms and the genotype concordance was >99.5%.
RIN3 mRNA expression and immunohistochemistry
Total RNA was isolated from adult mouse tissue/cultured pri-
mary cells and complementary DNA was generated by RT–PCR
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using the qScript cDNA SuperMix kit (QuantaBioscience) follow-
ing the manufacturer’s instructions. Expression of RIN3 mRNA
wasmeasured by quantitative real-time PCR using Roche univer-
sal library probe system (Roche). A FAM-labelled probe (universal
library probe 13: AGGCAGAG) was used to detect RIN3 transcripts
along with the following primer pair: forward, 5′GCCGGTCC
TATTCCAGATG3′ and reverse, 5′AAGAACTGAGCCTTCCAGGTA3′.
Real-time PCRwas performed using SensiFAST Probe kit (Bioline)
on a Chromo 4TM thermocycler (M J Research). RIN3 expression
levels were normalized to 18S rRNA which was determined
using the VIC-labelled probe-primer combination from Applied
Biosystems. Primary osteoblasts were isolated from the calvarial
bones of 2-day-old mice by sequential collagenase/EDTA diges-
tion and cultured in osteogenic medium (αMEM supplemented
with 50 μg/ml vitamin C and 3 m β-glycerol phosphate) for 21
days. To generate osteoclasts, bone-marrow cells were isolated
from the long bones of 4-month-old mice and cultured for 48 h in
the presence of M-CSF (100 ng/ml). Adherent cells were then sti-
mulated with M-CSF (25 ng/ml) and RANKL (100 ng/ml) for 4 days
until osteoclasts were formed. Osteoclasts were conﬁrmed by tar-
trate-resistant acid phosphatase (TRAP) staining using a standard
protocol. RIN3 expression in formalin-ﬁxed parafﬁn-embedded
(FFPE) human tissue sectionswas assessed by immunohistochem-
istry using RIN3 antibody (Sigma, cat number HPA039836) follow-
ing a standard protocol. Sections of normal lung tissue from a
patient with lung carcinoma and sections from a non-Pagetic
case of giant cell tumour of bone were used with ethical approval.
Data analysis
Association analysis of commonSNVswas performedusing χ2 al-
lelic test and for rare SNVsweused Fisher’s exact test. Burden test
was performed on all SNPs with MAF < 1% (in our cases and/or
controls) using Fisher exact test. Conditional analysis was per-
formed using logistic regression implemented in PLINK v1.07
(40). Haplotype analysis was performed using Haploview (41).
RIN3 expression data were analysed using a two-tailed t-test.
Functional annotation and assessing the impact of
missense variants on structure
The regulatory regionswithin the area of interest were annotated
using the Ensembl (www.ensembl.org) and ENCODE databases
(www.genome.gov/encode) to predict their functional signiﬁ-
cance, that included assessment of transcription factor binding
sites, splice-site loss or gain and known microRNA binding
sites. The functional effects of protein coding variants was as-
sessed using the following bioinformatics pathogenicity predic-
tors: SIFT (42), PolyPhen-2 (43), Condel (44), MutationTaster (45),
GERP conservation (46) and Grantham scores (47). A composite
functionality score was devised in which each variant was as-
signed a score of one point for each assessment tool if it met
the following criteria: predicted damaging by SIFT; predicted pos-
sibly or probably damaging by PolyPhen-2; predicted deleterious
by Condel; predicted disease causing by MutationTaster, had a
GERP score >2.0, or had a Grantham score >50. The functionality
score ranges from 0 (low functional probability) to 6 (high func-
tional probability).
Homologymodelling of the SH2 andVPS9domains of RIN3was
undertaken using Modeller 9v12 (48). FoldX (24,25) was used to es-
timate the free energy difference [stability change, expressed as
delta delta Gibbs free energy (ΔΔG)] upon mutagenesis from
wild-type. Meta-server consensus disorder predictor programs
metaPrDOS (17) and MetaDisorder (18) were used to undertake
disorder predictions on the full-length protein. PONDR VL-XT dis-
order predictions (www.molecularkinetics.com) (15) were carried
out on full-length wild-type and each mutated protein sequence,
generated by changing each of the variant residues individually.
Supplementary Material
Supplementary Material is available at HMG online.
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